Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.

<h4>Introduction</h4>Agonistic antibodies targeting TRAIL-receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are being developed as a novel therapeutic approach in cancer therapy including pancreatic cancer. However, the cellular distribution of these receptors in primary pancreatic cancer samples has not be...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Eike Gallmeier, Dominik C Bader, Lydia Kriegl, Sabina Berezowska, Hendrik Seeliger, Burkhard Göke, Thomas Kirchner, Christiane Bruns, Enrico N De Toni
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2013-01-01
coleção:	PLoS ONE
Acesso em linha:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23460812/pdf/?tool=EBI
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!